Polio - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Polio - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Polio - Pipeline Review, H1 2015', provides an overview of the Polio's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Polio, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polio and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Polio
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Polio and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Polio products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Polio pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Polio
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Polio pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Polio Overview 8
Therapeutics Development 9
Pipeline Products for Polio - Overview 9
Pipeline Products for Polio - Comparative Analysis 10
Polio - Therapeutics under Development by Companies 11
Polio - Therapeutics under Investigation by Universities/Institutes 12
Polio - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Polio - Products under Development by Companies 17
Polio - Products under Investigation by Universities/Institutes 18
Polio - Companies Involved in Therapeutics Development 19
Beijing Minhai Biotechnology Co., Ltd 19
Beijing Tiantan Biological Products Co., Ltd. 20
Bharat Biotech International Limited 21
Biological E. Limited 22
Codagenix, Inc. 23
Grifols, S.A. 24
Panacea Biotec Limited 25
Sanofi Pasteur SA 26
Sentinext Therapeutics Sdn Bhd 27
Sinovac Biotech Ltd. 28
Polio - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Combination Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
immune globulin (human) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
IPVGVI-3000 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
polio (bivalent) virus like particle vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
polio (monovalent) vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
polio [sabin] vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
polio vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
polio vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
polio vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
polio vaccine [types 1, 2, 3] (monovalent) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
poliomyelitis vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
PR-5I - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
V-073 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Polio - Recent Pipeline Updates 58
Polio - Dormant Projects 59
Polio - Discontinued Products 60
Polio - Product Development Milestones 61
Featured News & Press Releases 61
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables

Number of Products under Development for Polio, H1 2015 9
Number of Products under Development for Polio - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Polio - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 19
Polio - Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 20
Polio - Pipeline by Bharat Biotech International Limited, H1 2015 21
Polio - Pipeline by Biological E. Limited, H1 2015 22
Polio - Pipeline by Codagenix, Inc., H1 2015 23
Polio - Pipeline by Grifols, S.A., H1 2015 24
Polio - Pipeline by Panacea Biotec Limited, H1 2015 25
Polio - Pipeline by Sanofi Pasteur SA, H1 2015 26
Polio - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2015 27
Polio - Pipeline by Sinovac Biotech Ltd., H1 2015 28
Assessment by Monotherapy Products, H1 2015 29
Assessment by Combination Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Polio Therapeutics - Recent Pipeline Updates, H1 2015 58
Polio - Dormant Projects, H1 2015 59
Polio - Discontinued Products, H1 2015 60